NO20054778L - Farmasoytiske sammensetninger som innbefatter en kombinasjon av rapamycin eller dets derivat og pimecrolimus for behandling av inflamasjon- og immunologisk-medierte sykdommer - Google Patents

Farmasoytiske sammensetninger som innbefatter en kombinasjon av rapamycin eller dets derivat og pimecrolimus for behandling av inflamasjon- og immunologisk-medierte sykdommer

Info

Publication number
NO20054778L
NO20054778L NO20054778A NO20054778A NO20054778L NO 20054778 L NO20054778 L NO 20054778L NO 20054778 A NO20054778 A NO 20054778A NO 20054778 A NO20054778 A NO 20054778A NO 20054778 L NO20054778 L NO 20054778L
Authority
NO
Norway
Prior art keywords
rapamycin
inflammatory
treatment
combination
pharmaceutical compositions
Prior art date
Application number
NO20054778A
Other languages
English (en)
Other versions
NO20054778D0 (no
Inventor
Henrietta Moore
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33032928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20054778(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0306070A external-priority patent/GB0306070D0/en
Priority claimed from GB0306868A external-priority patent/GB0306868D0/en
Priority claimed from GB0319226A external-priority patent/GB0319226D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20054778D0 publication Critical patent/NO20054778D0/no
Publication of NO20054778L publication Critical patent/NO20054778L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

Den foreliggende oppfinnelsen vedrører farmasøytiske sammensetninger som i kombinasjon innbefatter rapamycin eller et rapamycinderivat og en forbindelse med formel 1, som for eksempel er nyttige ved behandling av inflammatorisk- og immunoligskmedierte sykdommer, inkludert autoimmune sykdommer
NO20054778A 2003-03-17 2005-10-17 Farmasoytiske sammensetninger som innbefatter en kombinasjon av rapamycin eller dets derivat og pimecrolimus for behandling av inflamasjon- og immunologisk-medierte sykdommer NO20054778L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0306070A GB0306070D0 (en) 2003-03-17 2003-03-17 Organic compounds
GB0306868A GB0306868D0 (en) 2003-03-25 2003-03-25 Organic compounds
GB0319226A GB0319226D0 (en) 2003-08-15 2003-08-15 Organic compounds
PCT/EP2004/002714 WO2004082681A1 (en) 2003-03-17 2004-03-16 Pharmaceutical compositions comprising a combination of rapamycin or its derivative and pimecrolimus for the treatment of inflammation- and ummunologically-mediated diseases

Publications (2)

Publication Number Publication Date
NO20054778D0 NO20054778D0 (no) 2005-10-17
NO20054778L true NO20054778L (no) 2005-12-19

Family

ID=33032928

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054778A NO20054778L (no) 2003-03-17 2005-10-17 Farmasoytiske sammensetninger som innbefatter en kombinasjon av rapamycin eller dets derivat og pimecrolimus for behandling av inflamasjon- og immunologisk-medierte sykdommer

Country Status (25)

Country Link
US (1) US20060154952A1 (no)
EP (1) EP1608368B8 (no)
JP (1) JP2006515017A (no)
KR (1) KR100855140B1 (no)
AR (1) AR043504A1 (no)
AT (1) ATE409479T1 (no)
AU (1) AU2004222563B2 (no)
BR (1) BRPI0408423A (no)
CA (2) CA2517671A1 (no)
CL (1) CL2004000535A1 (no)
DE (1) DE602004016830D1 (no)
EC (1) ECSP056006A (no)
ES (1) ES2315648T3 (no)
HR (1) HRP20050800A2 (no)
IS (1) IS8028A (no)
MA (1) MA27671A1 (no)
MX (1) MXPA05009934A (no)
MY (1) MY137868A (no)
NO (1) NO20054778L (no)
PE (1) PE20050313A1 (no)
PL (1) PL1608368T3 (no)
PT (1) PT1608368E (no)
TN (1) TNSN05197A1 (no)
TW (2) TW200835484A (no)
WO (1) WO2004082681A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050461A1 (en) * 2004-10-28 2006-05-11 Wyeth Use of an mtor inhibitor in treatment of uterine leiomyoma
EP2278966B1 (en) * 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
AU2013205002B2 (en) * 2008-03-21 2016-09-15 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
US20110274650A1 (en) 2009-01-21 2011-11-10 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
RU2449806C1 (ru) * 2010-11-30 2012-05-10 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ лечения красного плоского лишая слизистой оболочки полости рта
WO2014117035A1 (en) 2013-01-24 2014-07-31 Transderm, Inc. COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS
JP6529012B2 (ja) 2013-10-08 2019-06-12 エイアイ・セラピューティクス・インコーポレーテッド リンパ脈管筋腫症の処置のためのラパマイシン
NZ724756A (en) * 2014-04-04 2023-07-28 Ai Therapeutics Inc An inhalable rapamycin formulation for treating age-related conditions
AU2015330905B2 (en) 2014-10-07 2021-02-25 AI Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
MX2017012966A (es) 2015-04-10 2018-06-06 Amgen Inc Muteinas de interleuquina 2 para la expansion de celulas t regulatorias.
AU2018205253B2 (en) 2017-01-06 2022-01-13 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
UY38836A (es) 2019-08-13 2021-02-26 Amgen Inc Muteínas de interleucina-2 para la expansión de células t reguladoras

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0427680T3 (da) * 1989-11-09 1995-12-18 Sandoz Ltd Heteroatom-holdige cykliske forbindelser
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
WO1998004279A1 (en) * 1996-07-30 1998-02-05 Novartis Ag Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
JP2005512946A (ja) * 2001-05-09 2005-05-12 ノバルティス アクチエンゲゼルシャフト 選択的免疫調節法
HUP0402594A3 (en) * 2002-01-10 2006-01-30 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof
DE50310322D1 (de) * 2002-05-09 2008-09-25 Hemoteq Ag Hemokompatibel beschichtete medizinprodukte, deren herstellung und verwendung

Also Published As

Publication number Publication date
ES2315648T3 (es) 2009-04-01
TW200835484A (en) 2008-09-01
CL2004000535A1 (es) 2005-01-14
MA27671A1 (fr) 2005-12-01
MY137868A (en) 2009-03-31
AU2004222563B2 (en) 2006-11-02
AU2004222563A1 (en) 2004-09-30
WO2004082681B1 (en) 2004-11-25
NO20054778D0 (no) 2005-10-17
KR100855140B1 (ko) 2008-08-28
MXPA05009934A (es) 2006-03-21
AR043504A1 (es) 2005-08-03
EP1608368B8 (en) 2009-06-10
PL1608368T3 (pl) 2009-03-31
US20060154952A1 (en) 2006-07-13
ECSP056006A (es) 2006-01-27
TW200503703A (en) 2005-02-01
KR20050110023A (ko) 2005-11-22
WO2004082681A1 (en) 2004-09-30
PT1608368E (pt) 2009-01-27
HK1086743A1 (en) 2006-09-29
CA2633287A1 (en) 2004-09-30
CA2517671A1 (en) 2004-09-30
HRP20050800A2 (en) 2006-11-30
ATE409479T1 (de) 2008-10-15
EP1608368A1 (en) 2005-12-28
IS8028A (is) 2005-09-15
BRPI0408423A (pt) 2006-03-21
EP1608368B1 (en) 2008-10-01
JP2006515017A (ja) 2006-05-18
PE20050313A1 (es) 2005-06-14
TNSN05197A1 (en) 2007-06-11
DE602004016830D1 (de) 2008-11-13

Similar Documents

Publication Publication Date Title
NO20076059L (no) 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20063761L (no) Sulfonamidderivater for behandling av sykdommer
NO20051100L (no) Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
AP2008A (en) Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders; process for their preparation and pharmaceutical compositions containing them
DE60224404D1 (de) Substiuierte piperidine als melanocortinrezeptor-modulatoren
NO20070489L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
NO20062561L (no) Kinoliner nyttige for behandling av kardiovaskulaere sykdommer
EA200802058A1 (ru) Производные циклоалкиламинокислот и их фармацевтические композиции
NO20084005L (no) Aminderivater
ATE361288T1 (de) N-(3,-dimethylindolin-6-yl)ä2-ä(4-
NO20063928L (no) Substituerte kinolinforbindelser
DE602004024900D1 (de) Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren
NO20054905L (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
NO20062983L (no) Sulfonamid-derivater for behandling av sykdommer
IS6097A (is) Frumuviðloðunar-bælandi bólgu-eyðandi og ónæmisbælandi efnasambönd
NO20061363L (no) Pyrazolo- og imidazo- pyrimidinderivater
NO20060278L (no) Piperazinderivater og fremgangsmater for anvendelse
NO20073170L (no) Kaspaseinhibitorer og anvendelse derav
ATE406353T1 (de) Piperidin-derivaten und deren verwendung bei der behandlung von durch chemokinen oder h1 vermittelten krankheiten
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
NO20062256L (no) Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
MXPA05009934A (es) Composiciones farmaceuticas que comprenden una combinacion de rapamicina o su derivado y pimecrolimus para el tratamiento de enfermedades inflamatorias e inmunologicamente mediadas.
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application